Skip to main content
Have a personal or library account? Click to login
Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze Cover

Cannabis as a Possible Treatment for Spasticity in Multiple Sclerosis / Kanabis Kao Moguci Tretman U Lecenju Spasticnosti Kod Multiple Skleroze

EABR. Experimental and Applied Biomedical Research
Volume 17 (2016): Issue 1 (March 2016)
By: ,  ,  ,   and    
Open Access
|Apr 2016
References

References

  1. 1. Zuardi AW. History of cannabis as a medicine:a review. Rev Bras Psiquiatr.2006; 28 (2): 153-7.
    Open DOISearch in Google Scholar
  2. 2. Guy G, Whittle BA, Robson PJ. Medical Uses of Cannabis and Cannabinoids. London: Pharmaceutical Press. 2004.
    Search in Google Scholar
  3. 3. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964; 86: 1646-1647.
    Open DOISearch in Google Scholar
  4. 4. Matsuda LA, Bonner TI and Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol. 1993; 327: 535-550.
    Open DOISearch in Google Scholar
  5. 5. Munro S, Thomas KL and Abu-Sharr M. Molecular characterization of a peripheral receptor for cannabinoids. Nature.1993; 365: 61-65.
    Open DOISearch in Google Scholar
  6. 6. Iversen L.Cannabis and the brain: Review. Brain.2003 Jun; 126 (6): 1252-70.
    Open DOISearch in Google Scholar
  7. 7. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR and Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991; 11: 563-583.
    Open DOISearch in Google Scholar
  8. 8. Hohmann AG, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol. 1999; (81): 575-583.
    Open DOISearch in Google Scholar
  9. 9. Sanudo-Pena MC, Strangman NM, Mackie K, Walker JM and Tsou K. CB1 receptor localization in spinal cord and roots, dorsal root ganglion and peripheral nerve. Acta Pharmacol Sin. 1999; (12): 1115-1120.
    Search in Google Scholar
  10. 10. Vaughan VW, Connor M, Bagley EE and Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol. 2000; (57): 288-295.
    Search in Google Scholar
  11. 11. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alchol. 2005; Vol.40 (1): 2-14.
    Open DOISearch in Google Scholar
  12. 12. Wegener N, Koch_M. Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry 2009; 42 (1): 79-86
    Open DOISearch in Google Scholar
  13. 13. Petrosino S., Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 2010; 11: 51-62.
    Search in Google Scholar
  14. 14. Matthew J. McFarland, Ekaterina A.Terebova and Eric L. Barker. Detergent-Resistant Membrane Microdomains in the Disposition of the Lipid Signaling Molecule Anandamide. 2005 AAPS National Biotechnology Conference Symposium on Lipidomics. 2006: 95-100.
    Open DOISearch in Google Scholar
  15. 15. Colls BM, Ferry DG, Gray AJ, Harvey VJ, McQueen EG. The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patient undergoing cancer chemotherapy. N Z Med J.1980; (91): 449-451.
    Search in Google Scholar
  16. 16. McCabe M, Smith FP, Goldberg D, Macdonald J, Wooley PV, Warren R. Efficacy of tetrahydrocannabinol in patient refractory to standard antiemetic therapy. Invest New Drugs. 1988; (6): 243-246.
    Open DOISearch in Google Scholar
  17. 17. Duran M, Perez E, Abanades S et al. Preliminary efficacy and safety of an oromuscular standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacology. 2010; (70): 656-663.
    Open DOISearch in Google Scholar
  18. 18. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Sympt Manag.1995; (10): 89-97.
    Open DOISearch in Google Scholar
  19. 19. Strasser F, Luftner D, et al. Canabis in cachexia study group.Comparasion of orally administreted canabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double- blind, placebo-controlled clinical trial from the Cnnabis in cachexia study group. J Clin Oncol. 2006; (24): 3394-3400.
    Open DOISearch in Google Scholar
  20. 20. Volicer L,Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patinets with Alzheimer’s disease. Int J Geriatr Psychiatry.1997; (12): 913-919.
    Open DOISearch in Google Scholar
  21. 21. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain. 2007; (133): 210-220.
    Open DOISearch in Google Scholar
  22. 22. Rog DJ, Nurmikko TJ, Friede T, Young CA.Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology.2005; (65): 812-819.
    Open DOISearch in Google Scholar
  23. 23. Seeling W,Kneer L, Buchele B, et al. Delta-9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative paip. Anaesthesist. 2006; (55): 391-400.
    Open DOISearch in Google Scholar
  24. 24. Muller-Vahl KR, Schneider U, Prevedel H, et al. 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:a 6-week randomized trial. J Clin Psychiatry. 2003; (64): 459-465.
    Open DOISearch in Google Scholar
  25. 25. Sieradzan KA, Fox SH,Dick J, Brotchie JM. The effects of the cannabinoid receptor agonist nabilone on L-dopa induced dyskinesia in patients with idiopathic Parkinon’s disease. Movement disorders.1998; 13 (Suppl 2).
    Search in Google Scholar
  26. 26. Nielsen JB, Crone C., Hultborn H. The spinal pathophysiology of spasticity-from a basic science point of view. Acta Physiologica 2007; 189: 171-180.
    Open DOISearch in Google Scholar
  27. 27. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL.Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler.2004; 10 (5): 589-595.
    Open DOISearch in Google Scholar
  28. 28. Crayton HJ, Rossman HS. Clinical Therapeutics 2006; 28 (4): 445-460.
    Search in Google Scholar
  29. 29. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess_2003; 7(40): 101-111.
    Open DOISearch in Google Scholar
  30. 30. Bhimani R, Anderson L. Clinical understanding of spasticity: implications for practice. Rehabil Res Pract.2014; 2014:279175. doi: 10.1155/2014/279175.
    Open DOISearch in Google Scholar
  31. 31. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med._2000; 160 (22): 415-420.
    Open DOISearch in Google Scholar
  32. 32. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev.2003; 4:CD001332.
    Open DOISearch in Google Scholar
  33. 33. Novotna A, Mares J, Ratcliffe S,et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched- design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011; 2-10.
    Open DOISearch in Google Scholar
  34. 34. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis.Nerurology.2004; 62:2098-2100.
    Open DOISearch in Google Scholar
  35. 35. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG et al. Endocannabinoids control spasticity in a multiple sclerosis model. Faseb J.2011; 15:300-302.
    Open DOISearch in Google Scholar
  36. 36. Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a doublelabel in situ hybridization study. Neuroscience.1999; 90(3): 923-931.
    Open DOISearch in Google Scholar
  37. 37. Pertwee RG.Cannabinoid receptors and pain. Prog Neurobiology.2010; 63(5): 569-611.
    Open DOISearch in Google Scholar
  38. 38. Baker D., Pryce G., Jackson SJ., Bolton C., Giovannoni G. The biology that underpins the terapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Multiple sclerosis and Related Disordes 2012; 64: 64-75.
    Open DOISearch in Google Scholar
  39. 39. Kmietowicz Z. Cannabis based drug is licensed for spasticity in patients with MS. British Medical Journal 2010; 340: c 3363.
    Open DOISearch in Google Scholar
  40. 40. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg.Med.Chem. 2015; http://dx.doi.org/10.1016/ j.bmc 2015.01.059.
    Search in Google Scholar
  41. 41. Russo E. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011; 163: 1344-1364.
    Open DOISearch in Google Scholar
  42. 42. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother. 2006; 7 (5): 607-15.
    Open DOISearch in Google Scholar
  43. 43. Collin C, Ehler E,Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subject with symptoms of spasticity due to multiple sclerosis. Neurol Res.2010; 32(5): 451-459.
    Open DOISearch in Google Scholar
  44. 44. Ashton C John. Emerging treatment options for spasticity in multiple sclerosis-clinical utility of cannabinoids. Degenerative Neurological and Neuromuscular Disease. 2011; 15-23.
    Open DOISearch in Google Scholar
  45. 45. Tkaczyk M, Florek E, Piekoszewski W. Marihuana and cannabinoids as medicaments. Przegl Lek. 2012; 69 (10): 1095-97.
    Search in Google Scholar
  46. 46. Iversen L. Long-termeffects of exposure to canabis. Curr Opin Pharmacol. 2005;5 (1):69-72 Radhakrishnan R., Wilkinson S. and D Souza DC. Gone to pot-a review of the association between cannabis and psychosis. Frontiers in psychiatry 2014; 54 (5): 1-24.
    Search in Google Scholar
  47. 47. Radhakrishnan R., Wilkinson S. and D Souza DC. Gone to pot-a review of the association between cannabis and psychosis. Frontiers in psychiatry 2014; 54 (5): 1-24.
    Search in Google Scholar
  48. 48. Wang T, Collet JP, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008; 178 (13): 1669-1678.
    Open DOISearch in Google Scholar
  49. 49. Perez J.Combined cannabinoid therapy via an oromuscular spray. Drugs of Today.2006; 42: 495-503.
    Open DOISearch in Google Scholar
  50. 50. Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders. CNS Neurosci Ther. 2009; 15: 65-75.
    Open DOISearch in Google Scholar
  51. 51. Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother.2013; 12: 49-54).
    Open DOISearch in Google Scholar
  52. 52. www.mhra.gov.uk. Scheduling of the cannabis-based medicine ‘Sativex’ Accessed in April 2015. Published: 27 March 2013.
    Search in Google Scholar
  53. 53. Barbara S. Koppel, John C.M. Brust, Terry F, Jeff Bronstein,Sarah Youssof, Gary Gronseth and David Gloss. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Neurology. 2014; 82_(17):_1556-1563.
    Open DOISearch in Google Scholar
  54. 54. Wright S.,Yadav V., Bever C Jr et al. Summary of evidence- based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology._2014; 83 (16):1484-1486.
    Open DOISearch in Google Scholar
  55. 55. Potter DJ. A rivew of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal. 2014; 6 (1-2): 31-38.
    Open DOISearch in Google Scholar
  56. 56. www.zdravlje.gov.rs Zakon o psihoaktivnim kontrolisanim supstancama. Službeni glasnik Republike Srbije br.99/10. Accessed in April 2015.
    Search in Google Scholar
  57. 57. Arroyo R, Vila C, Dechant KL. Impact of Sativex(®) on_quality of life_and activities of daily living in patients with multiple sclerosis spasticity.J Comp Eff Res. 2014; 3(4):435-44. doi: 10.2217/cer.14.30.
    Open DOISearch in Google Scholar
  58. 58. Slof J, Gras A. Sativex in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res. 2012; 12 (4): 439-441
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/sjecr-2015-0047 | Journal eISSN: 2956-2090 (formerly 2335-075X, 2956-0454) | Journal ISSN: 2956-0454 (formerly 1820-8665)
Journal RSS Feed
Language: English
Page range: 61 - 66
Submitted on: Mar 4, 2015
Accepted on: May 14, 2015
Published on: Apr 14, 2016
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Keywords:
cannabis,
multiple sclerosis,
spasticity,
nabiximols
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2016 Katarina Vesic, Slavica Djukic Dejanovic, Milica Borovcanin, Janko Samardzic, Gordana Toncev, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 17 (2016): Issue 1 (March 2016)
Previous article
Next article